Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL), a pharmaceutical company developing cannabis-infused drugs and psychedelic-assisted psychotherapy protocols, has welcomed three world-renowned psychedelic therapy and science experts to its Clarion Clinics Group Advisory Board.
The Clarion Clinics Groups Pty Ltd is a collaborative venture between Incannex and three leading Australian psychedelics experts - Dr Paul Liknaitzky, Professor Suresh Sundram and Sean O’Carroll.
They will be joined by three more renowned psychedelic professionals - Dr Bill Richards, Dr Andrea Jungaberle and Professor Matthew Johnson.
“I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team,” Incannex Healthcare director Peter Widdows said.
“It’s a testament to the vision that Paul, Suresh and Sean are bringing together to provide this vital service to many people in great need.
“As Australia is the first country to legalise the use of psychedelic drugs in the treatment of mental illness, the eyes of the world are upon us, and having people of this calibre and experience on board will help us ensure we provide world-leading effective treatments in an ethical and safe way.”
Clarion’s first clinic will open its doors to patients in the third quarter of this year, and the company intends to expand rapidly following the successful operation of the first clinic.
Pioneering mental health treatment
“When people with the global reputations of Bill, Matthew and Andrea wish to help shape your venture, you know you’ve hit on something special; something which could help improve the lives of millions of people around the world,” Incannex Healthcare managing director and CEO Joel Latham said.
Dr Bill Richards is the director of therapy at Sunstone Therapies, a psychologist in the Centre for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine, a consultant/trainer within numerous psychedelic research sites internationally.
He’s also a teacher in the Program of Psychedelic Therapy and Research at the California Institute of Integral Studies, and a clinician in private practice in Baltimore.
Dr Andrea Jungaberle fills the role of chief medical officer of Ovid Clinics in Berlin and as co-founder of Europe’s leading psychedelic research group, the MIND Foundation.
Jungaberle is a clinical specialist in anaesthesia and emergency medicine, a psychedelic therapist, and currently completing a certification in cognitive behavioural psychotherapy.
She is a published author, workshop leader, yoga teacher, and has participated in several accredited trainings in psychedelic therapy.
Professor Matthew Johnson is a prolific psychedelic scientist who has played a key role at the Johns Hopkins Centre for Psychedelic & Consciousness Research.
He is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioural economics of drug use, addiction, and risk behaviour.
“Bill, Andrea and Matt are wonderful colleagues and inspiring people,” Clarion Clinics Group co-founder, director, chief strategy officer and chief scientific officer Dr Paul Liknaitzky said.
“Each bring deep experience and hard-won wisdom that will help guide our efforts within the Clarion venture towards supporting our clients to live their best lives.
“I’m grateful for their trust and support.”